FDA approved Epi proColon, a blood-based colorectal cancer screening test developed by Epigenomics AG. Epi proColon will be made available in the U.S. under a joint commercialization agreement with Epigenomics partner Polymedco. Epi proColon is indicated for colorectal cancer screening in average-risk patients who choose not to undergo colorectal cancer screening by guideline-recommended methods such...
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
